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https://doi.org/10.1016/j.celrep.2020.108140SUMMARYFBXL21 is a clock-controlled E3 ligase modulating circadian periodicity via subcellular-specific CRYPTO-
CHROMEdegradation. HowFBXL21 regulates tissue-specific circadian physiology andwhatmechanismoper-
atesupstreamispoorlyunderstood.Herewereport thesarcomerecomponentTCAPasacytoplasmicsubstrate
of FBXL21. FBXL21 interactswithTCAP ina circadianmanner antiphasic toTCAPaccumulation in skeletalmus-
cle, and circadian TCAP oscillation is disrupted in Psttm mice with an Fbxl21 hypomorph mutation. GSK-3b
phosphorylates FBXL21 and TCAP to activate FBXL21-mediated, phosphodegron-dependent TCAP degrada-
tion. GSK-3b inhibition or knockdown diminishes FBXL21-Cul1 complex formation and delays FBXL21-medi-
ated TCAP degradation. Finally, Psttmmice show significant skeletal muscle defects, including impaired fiber
size, exercise tolerance, grip strength, and response toglucocorticoid-inducedatrophy, in conjunctionwith car-
diac dysfunction. These data highlight a circadian regulatory pathway where a GSK-3b-FBXL21 functional axis
controls TCAP degradation via SCF complex formation and regulates skeletal muscle function.INTRODUCTION
The mammalian circadian clock regulates tissue-specific gene
expression to control metabolism, physiology, and behavior (Ce-
derroth et al., 2019; Takahashi, 2017). The functional unit of the
circadian clock is a cell-autonomous molecular oscillator
composed of auto-regulatory transcriptional-translational feed-
back loops of clock genes encoding positive (CLOCK, NPAS2,
BMAL1, and RORs) and negative (PER1/2, CRY1/2, and REV-
ERBs) components (Takahashi, 2017). The oscillator is governed
by a complex mechanism encompassing transcriptional, post-
transcriptional, and post-translational regulatory steps (Gallego
and Virshup, 2007; Green, 2018). In particular, ubiquitination-
mediated proteasomal degradation is a critical post-translational
mechanism in circadian oscillation, controlling clock protein
degradation at the end of a circadian cycle prior to starting a
new one (Stojkovic et al., 2014). The ubiquitination cascade in-
volves serial enzymatic reactions by an E1 ubiquitin-activating
enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiqui-
tin ligase (Hershko et al., 1983). E3 ubiquitin ligases recognize
and attach ubiquitin (Ub) to substrate proteins; therefore, they
are mainly responsible for target specificity and downstream
processes. Various E3 ligases and deubiquitinases regulateCe
This is an open access article unddegradation of core clock proteins (Gallego and Virshup, 2007;
Stojkovic et al., 2014), although their functions and regulatory
mechanisms in circadian physiology are not well understood.
F box E3 ligases are characterized by F box domains spanning
50 amino acids. F box domains mediate formation of SCF Ub-
ligase complexes, each containing Skp1, Cullin, and F box pro-
teins, for Ub-mediated proteolysis (Kipreos and Pagano, 2000). F
box proteins are known to regulate circadian rhythmicity in various
model systems (Busino et al., 2007; Dardente et al., 2008; Eide
et al., 2005; Godinho et al., 2007; Grima et al., 2002; Harmon and
Kay, 2003; He et al., 2003; Hirano et al., 2013; Imaizumi et al.,
2003; Ko et al., 2002; Koh et al., 2006; Shirogane et al., 2005;
Siepka et al., 2007; Somers et al., 2004; Yoo et al., 2013). Previous
reports illustrate functional and mechanistic interplay between pa-
ralogous E3 ligases (Adler et al., 2017; Fuchs et al., 2004; Scott
et al., 2016; Siepka et al., 2007; Yoo et al., 2013). Although
b-TRCP1andb-TRCP2appear tobe largely redundant insubstrate
recognition anddegradation (Fuchs et al., 2004),weandothers un-
covered an unexpected functional antagonism between the circa-
dian E3 ligases F-box/LRR-repeat protein 3 and 21 (FBXL3 and
FBXL21). Hypomorphic Fbxl3 mutations were initially found to
lengthen the circadian period and stabilize CRY proteins by atten-
uating SCF-FBXL3-mediated proteasomal degradation (Businoll Reports 32, 108140, September 15, 2020 ª 2020 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Identification of TCAP as a FBXL21 Substrate
(A) Y2H test showing that FBXL3 and FBXL21 interact with TCAP. Positive control yeasts were transformed with the pGBKT7-p53 bait plasmid and the pGADT7-
SV40 Tag prey plasmid. pGBKT7-53 encodes the Gal4 DNA binding domain (BD) fused with murine p53; pGADT7-T encodes the Gal4 activation domain (AD)
fused with SV40 large T antigen.
(B) Interaction of FBXL3 and FBXL21 with TCAP. 293T cells were transfected with FLAG-Fbxl3, FLAG-Fbxl21, and hemagglutinin (HA)-TCAP, and immuno-
precipitation was performed using anti-FLAG antibody (M2).
(C andD) FBXL21, but not FBXL3, decreases the TCAP amount in a dose-dependentmanner. 293T (C) andC2C12 (D) cells were co-transfectedwith the indicated
constructs. The graphs below showquantification of the dose effects of FBXL3 and FBXL21 on TCAP stability using unnormalized optical density (OD) values, and
(legend continued on next page)






OPEN ACCESSet al., 2007; Godinho et al., 2007; Siepka et al., 2007). More
recently, we reported a short-period circadian mutant, Past-time
(Psttm; indicating thehomozygousmutantFbxl21Psttm/Psttm),where
themutationwasmapped to a gene encoding FBXL21, a homolog
of FBXL3 (Yoo et al., 2013). Unexpectedly, the reduced level and
activity of FBXL21 in Psttm led to destabilization of CRY proteins.
Mechanistic studies revealed an unusual dual function of
FBXL21. On one hand, FBXL21 forms an SCF E3 ligase complex
that slowly degrades CRY in the cytoplasm, and on the other
hand, it antagonizes the stronger E3 ligase activity of FBXL3 in
the nucleus by sequestering CRY from FBXL3. Fbxl21 is also a
clock-controlledgene (Dardenteetal., 2008); its transcript andpro-
tein levels exhibit circadian oscillation (Yoo et al., 2013). Another
study also described antagonism of FBXL3 and FBXL21 for CRY
degradation but proposed a mechanism involving heterogeneous
ubiquitination chains (Hirano et al., 2013). Identification of addi-
tional protein substrates will provide mechanistic insights and
reveal how these FBXLs regulate circadian physiology.
Regulation of F box proteins could impinge on multiple steps,
including synthesis, dimerization, degradation, and SCF activity
(Lee and Diehl, 2014; Skaar et al., 2013; Wang et al., 2014;
Welcker et al., 2013). Particularly, neddylation at the C terminus
of CULLIN1 induces structural rearrangement in its backbone,
increasing SCF E3 ligase activity (Lydeard et al., 2013). In contrast
to themolecular mechanisms that regulate F box protein function,
upstream cellular signaling for most F box proteins in SCF com-
plex formation and E3 ligase activation remains largely unclear.
Studies have indicated a role of post-translational modifications
(PTMs), including sumoylation and particularly phosphorylation,
in altering the subcellular localization and E3 ligase activity of F
box proteins (Fuchs et al., 2002; Gao et al., 2009; Jura et al.,
2006; Lin et al., 2009; Wang et al., 2018; Xu et al., 2010). How
FBXL21 activity is regulated upstream is largely unknown.
To identify additional cellular targets and regulatory mecha-
nisms of FBXL21, we conducted a yeast 2-hybrid (Y2H) screen
and found that Telethonin, also known as Titin cap or TCAP (Valle
et al., 1997), is a cytoplasmic substrate of FBXL21. Mechanistic
studies revealed circadian regulation of TCAP ubiquitination by
FBXL21 and uncovered a nodal regulatory function of the
GSK-3b-FBXL21 axis in SCF complex formation, substrate turn-
over, and muscle function.RESULTS
Identification of TCAP as a Cytoplasmic Substrate of
FBXL21
To further dissect the cellular mechanisms of FBXL21, we per-
formed a Y2H screen for putative target substrates using a hu-error bars represent ± SEM (n = 4). TCAP abundance shows a significant statistica
and C2C12 cells (t test, **p < 0.01, ***p < 0.001, ****p < 0.0001).
(E) Top left panel: FBXL21 showed anti-phase oscillation with TCAP in skeleta
normalized OD values. Error bars represent ± SEM (n = 3). Two-way ANOVA sho
Bonferroni’s multiple comparisons test shows a significant difference at ZT16 (p
shows a statistically significant differences in the FBXL21 amount between time p
time-dependent TCAP-FBXL21 interaction.
(F) Differential localization of FBXL3 and FBXL21 in 293T cells. Scale bars, 20 mm
See also Figure S1.man skeletal muscle expression library, given the important
role of the clock in skeletal muscle (Harfmann et al., 2015). The
established substrate CRY2 was used as a positive control (Fig-
ure S1A). TCAP, a core sarcomeric component capping the titin
proteins, was identified as a positive hit (Figure 1A). TCAP is a
small (19 kDa), highly abundant cytoplasmic protein expressed
exclusively in skeletal muscle and the heart (Valle et al., 1997).
TCAP interacts with titin through its N-terminal b sheet to anchor
titin to the Z-disc (Gregorio et al., 1998; Mues et al., 1998; Pinot-
sis et al., 2006), and TCAP deficiency in mice and humans
causes dysfunction in heart and skeletal muscle. Interestingly,
TCAP mRNA and its protein product display robust circadian
expression (Podobed et al., 2014). To validate TCAP as a
possible circadian substrate of FBXLs, we co-expressed TCAP
with FBXL21 and FBXL3 in 293T cells and performed co-immu-
noprecipitation. FBXL21 and FBXL3 were found to bind to TCAP
(Figure 1B). However, ectopic expression of FBXL21, but not
FBXL3, dose-dependently destabilized TCAP in 293T and
C2C12 cells, suggesting that FBXL21 functions as the primary
E3 ligase for cytoplasmic TCAP proteins (Figures 1C and 1D).
To define in vivo interaction between TCAP and FBXLs, we
performed co-immunoprecipitation using gastrocnemius mus-
cles collected from wild-type (WT) C57BL/6 mice during one
12 h:12 h light:dark (LD) circadian cycle every 4 h at the indicated
zeitgeber time (ZT). Although FBXL3 did not show any significant
interaction with TCAP throughout the circadian cycle, presum-
ably because of the distinct localization of TCAP (strictly cyto-
plasmic; Valle et al., 1997) and FBXL3 (predominantly nuclear;
Siepka et al., 2007), FBXL21 and TCAP displayed circadian
oscillation of binding, peaking at ZT0–ZT4 (Figure 1E).
Consistent with TCAP as a sarcomere component, ectopic
expression of TCAP showed cytoplasmic accumulation in 293T
cells (Figure 1F). When expressed alone, FBXL3 and FBXL21
were mainly localized in the nucleus and the cytoplasm, respec-
tively, as we reported previously (Figure 1F; Yoo et al., 2013). Co-
expression of TCAP led to FBXL3 distribution in the nucleus and
cytoplasm (Figure 1F), perhaps because their interaction did not
cause TCAP turnover (Figures 1C and 1D). FBXL21 and TCAP
co-localized in the cytoplasm, further suggesting a role of
FBXL21 in TCAP degradation.FBXL21 Directly Regulates TCAP Degradation by F Box-
Dependent Ubiquitination
Next we performed cycloheximide (CHX) chase assays to mea-
sure the effect of FBXLs on TCAP turnover. FBXL21 accelerated
TCAP degradation in 293T cells and C2C12 myoblast cells,
whereas FBXL3 activity was much less significant (Figures 2A
and S1B). For example, the TCAP half-life was estimated to bel difference between TCAP alone and different FBXL21 concentrations in 293T
l muscle. Right panels: quantification of FBXL21 and TCAP levels using un-
ws a significant statistical difference between TCAP and FBXL21 (p < 0.0001).
< 0.05) and ZT20 (p < 0.01). One-way ANOVA with Tukey’s post hoc analysis
oints (*p < 0.05). Bottom left panel: co-immunoprecipitation showing circadian
.
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Figure 2. FBXL21 Mediates TCAP Proteaso-
mal Degradation by Ubiquitination
(A) 293T cells were co-transfected with the indi-
cated constructs. Thirty-two hours after trans-
fection, cells were treated with 100 mg/mL CHX
and incubated for the indicated time before har-
vest. Immunoblotting was performed to detect
TCAP (25 kD) and FBXLs using anti-FLAG anti-
body. Right panel: quantification of the effect of
FBXL3 and FBXL21 on TCAP stability. Error bars
represent ± SEM (n = 3). Half-life was determined
by using nonlinear, one-phase decay analysis
(TCAP, 6.1 h, TCAP/FBXL3, 5.0 h, TCAP/FBXL21,
2.3 h; the half-life parameter, K, is significantly
different in Fbxl21 co-expression: p < 0.0001).
(B) Accelerated cytoplasmic TCAP degradation by
FBXL21 in the cytoplasm. Immunoblotting was
performed using cytoplasmic and nuclear fractions
with anti-FLAG antibody. Right panels: quantifi-
cation of cytoplasmic TCAP and nuclear TCAP.
Error bars represent mean ± SEM (n = 3). Half-life
was determined by using nonlinear, one-phase
decay analysis (CytoTCAP, 6.5 h; CytoTCAP/
FBXL21, 3.0 h, NuTCAP, 6.7 h; NuTCAP/FBXL21,
5.0 h; the half-life parameter, K, is significantly
different with Fbxl21 co-expression: p < 0.0001).
(C) MG132 inhibited TCAP degradation by
FBXL21.
(D) Knockdown of Fbxl21 increased TCAP
expression in 293T cells. Right panel: real-time RT-
PCR analysis of hFbxl21 mRNA expression (*p <
0.05).
(E) FBXL21-Cullin-1 complex formation in the
cytoplasm.
(F) TCAP ubiquitination by FBXL21.
See also Figure S1.
Article
ll
OPEN ACCESS6.1 h by itself and 5.0 h and 2.3 h with Fbxl3 and Fbxl21 co-trans-
fection, respectively, in 293T cells. We next compared the rates
of degradation and found that FBXL21 expression significantly
increased the TCAP degradation rate in the cytoplasm but not
in the nucleus (Figure 2B).4 Cell Reports 32, 108140, September 15, 2020To ascertain whether FBXL21-medi-
ated TCAP degradation is mediated by
ubiquitination-dependent proteasomal
degradation, we treated 293T cells with
the 26S proteasome inhibitor MG132
and observed inhibition of dose-depen-
dent TCAP degradation by FBXL21 (Fig-
ure 2C). Knockdown of endogenous
Fbxl21 in 293T cells by hFbxl21 small
interfering RNA (siRNA) transfection
increased TCAP accumulation compared
with control siRNA, suggesting that
endogenous FBXL21 regulates FLAG-
TCAP degradation (Figure 2D). Next we
investigated whether TCAP binding can
modulate subcellular FBXL21-CULLIN1
complex formation by co-immunoprecip-
itation. Previously, binding of the sub-
strate CRY1 to FBXL3 was found to pro-mote SCF complex formation (Yumimoto et al., 2013). In
contrast, FBXL21 formed active SCF E3 ligase complexes in
the cytoplasm, and TCAP ectopic expression did not increase
neddylated-CULLIN1-FBXL21 complex formation, which is
indicative of active E3 ligase activity (Figure 2E).
Figure 3. Identification of TCAP Ubiquitination Sites by FBXL21 and Altered TCAP Circadian Oscillation in Psttm Skeletal Muscle
(A) The five lysine sites in TCAP were individually mutated to arginine, and the stability of each K-to-R mutant was examined by co-transfecting the Fbxl21
expression construct into 293T cells.
(B) Impaired FBXL21-mediated degradation of the TCAP K26R/K98R mutant. Immunoblotting was performed to detect TCAP (25 kD) and FBXLs using anti-
FLAG antibody.
(C) Quantification of the effect of FBXL21 on WT TCAP and K26R/K98R stability. Error bars represent ± SEM (n = 3). Half-life: TCAP, 5.5 h, TCAP/FBXL21, 2.3 h,
TCAPK26R/K98R, 19.4 h, TCAPK26R/K98R /FBXL21, 9.4 h).
(D) TCAP oscillation in skeletal muscle from WT and Psttm mutant mice. Immunoblotting was performed using total protein extracts with TCAP antibody.
Representative blots from three independent experiments are shown, and quantification is shown in the right panel (error bars represent ± SEM, n = 3). One-way
ANOVA with Tukey’s post hoc analysis shows statistically significant differences in the TCAP amount between time points in WT (*p < 0.05) but not Psttmmice.
Two-way ANOVA shows significant statistical differences between WT and Psttm mice for TCAP expression (p < 0.01). Blue and red circles represent WT and
Psttm mice, respectively.
(E) Real-time RT-PCR analysis of TCAP mRNA expression in WT (blue) and Psttm (red) mice. Two-way ANOVA shows a significant statistical difference for TCAP
mRNA at ZT0 and ZT12 (error bars represent ± SEM, n = 3; ****p < 0.0001) but no significance between WT and Psttm mice.
See also Figure S2.
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OPEN ACCESSNext we performed ubiquitination assays by expressing
TCAP, FBXL21, and Ub in 293T cells in the presence of
MG132 (Figure 2F). FBXL21 co-expression enriched poly-ubiq-
uitinated TCAP compared with TCAP by itself, suggesting that
FBXL21 mediates TCAP ubiquitination (Figure 2F). MDM2 has
been reported to promote TCAP proteasomal degradation via
a mechanism independent of its ring domain (Tian et al., 2006).
In contrast, loss-of-function mutant FBXL21 with F box deletion
(Yoo et al., 2013) did not promote formation of poly-ubiquitinated
TCAP compared with the WT (Figure S1C). These results sug-
gest that, unlike MDM2 (Tian et al., 2006), FBXL21-mediatedTCAP ubiquitination entails direct Ub transfer from the SCF E3
ligase complex containing FBXL21.
Identification of TCAP Ubiquitination Lysine Sites by
FBXL21
To identify the ubiquitination sites required for TCAP degrada-
tion, the five lysines in TCAP were converted individually to
arginine. In an initial endpoint degradation assay with FBXL21
co-expression, the K26R and K98R mutations conferred resis-
tance to FBXL21-mediated TCAP degradation (Figure 3A).
Therefore, we generated a K26R/K98R double mutant andCell Reports 32, 108140, September 15, 2020 5
Figure 4. GSK-3b Regulates FBXL21-Mediated TCAP Degradation
(A) 293T cells were co-transfected with the indicated constructs. Twelve hours after transfection, cells were treated with the indicated kinase inhibitors for 24 h
before CHX treatment.
(legend continued on next page)






OPEN ACCESSperformed CHX degradation assays in 293T cells. As shown in
Figure 3B, the K26R/K98R double mutant displayed a signifi-
cantly reduced degradation rate with FBXL21 co-expression
relative to the WT TCAP (Figure 3C), indicating that FBXL21 tar-
gets K26 and K98 for ubiquitination-mediated proteasomal
degradation of TCAP.The Psttm Mutation Disrupted TCAP Protein Circadian
Oscillation
We examined the effect of the Fbxl21 hypomorph mutation
(Psttm, G149E) on TCAP circadian oscillation in skeletal muscle
and heart tissues. TCAP protein showed circadian oscillation in
WT tissues (Figures 3D and S2A); however, TCAP amounts
were significantly elevated and circadian oscillation was disrup-
ted in Psttmmouse tissues, whereas BMAL1 levels were largely
unaltered (Figure S2B).
We next performed qPCR to examine TCAP mRNA levels in
WT and Psttm skeletal muscle at ZT0 and ZT12, corresponding
to trough and peak points during its oscillation. The TCAPmRNA
level was markedly higher at ZT12 compared with ZT0 but not
significantly different between the WT and Psttm (Figure 3E),
suggesting that the increase in TCAP protein amount in Psttm
skeletal muscle is primarily due to impaired protein degradation.
These results strongly suggest that Fbxl21 functional impairment
leads to TCAP protein stabilization. Of note, the TCAP protein
level peaked at ZT8 in the WT (Figure 3D), a time when its inter-
action with FBXL21was largely abrogated (Figure 1E). This result
further indicates that FBXL21-mediated circadian proteasomal
degradation of TCAP contributes to TCAP protein oscillation in
addition to the rhythmic Tcap transcript levels, as reported pre-
viously (Hodge et al., 2019; Podobed et al., 2014).FBXL21 E3 Ligase Activity for TCAP Is Regulated by
GSK-3b
We next investigated the upstream regulatory mechanism for
FBXL21 activity. Given the reported regulatory phosphorylation
events in both substrates (phosphodegron) and E3 ligases (Fili-
pcik et al., 2017; Gao et al., 2009; Kazlauskaite et al., 2014; Lin
et al., 2009), we searched putative phosphorylation sites of
FBXL21 (phosphoScan, NetPhos3.1; Blom et al., 2004) and iden-
tified 5 candidate kinases with high scores (>0.45), including
GSK-3, DNA-PK, CDK, protein kinase C (PKC), and CK1. Using
specific inhibitors (CHIR-99021, GSK-3; NU7441, DNA-PK;
Ro3306, CDK; Sotrastaurin, PKC; IC261, CK1), protein degrada-
tion assays showed that the GSK-3 inhibitor CHIR-99021
strongly repressed FBXL21-mediated TCAP degradation (Fig-(B) Interaction of TCAP and FBXL21 with GSK-3b. 293T cells were transfected wi
performed using anti-FLAG antibody (M2).
(C) GSK-3b in vitro kinase assay. Affinity-purified FLAG-TCAP and FLAG-FBXL2
shows a significant statistical difference betweenmock (pCMV-3XFLAG empty ve
n = 3).
(D) GSK-3b ectopic expression accelerated TCAP degradation in an FBXL21-dep
of GSK-3b on TCAP stability. Error bars represent ± SEM (n = 3). Half-life: TCAP, 5
(E) The GSK-3 inhibitor CHIR-99021 decelerated FBXL21-mediated TCAP degrad
Error bars represent ± SEM (n = 3). Half-life: TCAP, 5.3 h; TCAP/CHIR-99021, 15
(F) GSK-3b knockdown decelerated FBXL21-mediated TCAP degradation. Right p
bars represent ± SEM (n = 3). Half-life: TCAP, 4.1 h; TCAP/GSK-3b shRNA, 32.0ure 4A). Because GSK-3b, but not GSK-3a, plays a crucial role
in muscle (Beurel et al., 2015; van der Velden et al., 2008; Ver-
hees et al., 2011), we focused on GSK-3b for muscle-specific
protein TCAP degradation.
To determine whether GSK-3b targets FBXL21 and/or TCAP,
we co-expressed GSK-3b with FBXL21 or TCAP in 293T cells
and performed co-immunoprecipitation. Interestingly, TCAP
and FBXL21 were found to bind to GSK-3b (Figure 4B), suggest-
ing that both could be GSK-3b substrates. We therefore con-
ducted in vitro kinase assays using affinity purified FLAG-TCAP
and FLAG-FBXL21, which showed that TCAP and FBXL21
were efficiently phosphorylated by GSK-3b (Figure 4C). Further-
more, ectopic expression of GSK-3b accelerated TCAP degra-
dation in a FBXL21-dependent manner (Figure 4D), providing
gain-of-function evidence of a role of FBXL21 in GSK-3b-regu-
lated TCAP degradation. In TCAP degradation assays using
293T cells, FBXL21-mediated TCAP degradation was signifi-
cantly retarded by CHIR-99021 (Figure 4E) or co-transfection
of GSK-3b shRNA (Figure 4F). These results demonstrate that
GSK-3b phosphorylates FBXL21 and TCAP and plays a regula-
tory role in FBXL21-mediated TCAP ubiquitination.Distinct Functional Mechanisms of GSK-3b-Mediated
Phosphorylation for TCAP and FBXL21
To identify the target phosphorylation sites of GSK-3b for TCAP
and FBXL21, we performed mass spectrometry. FLAG-tagged
TCAP and FBXL21 proteins were isolated by affinity purification
and analyzed by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) to determine phosphorylated sites. We
identified S157 and S161 phosphorylation in TCAP correspond-
ing to GSK-3b consensus phosphorylation sites (SXXXS) (Fig-
ure 5A). S157/S161 have been reported previously as protein ki-
nase D (PKD) phosphorylation sites in cardiac myocytes and to
be involved in t-tubule organization (Candasamy et al., 2014);
however, TCAP phosphorylation was not affected by PKD inhibi-
tion (Candasamy et al., 2014). To determine whether these sites
function as a phosphodegron for TCAP degradation by FBXL21,
we mutated both serine residues to alanine and performed CHX
half-life measurement of the TCAP S157A/S161A mutant. The
TCAP S157A/S161A mutant showed significantly retarded
FBXL21-mediated degradation, suggesting that these two sites
constitute a phosphodegron for ubiquitination-mediated degra-
dation by FBXL21 (Figure 5B).
Because of the size similarity between FLAG-tagged FBXL21
and immunoglobulin G (IgG) heavy chain, we were not able to
isolate single bands from affinity purification. Therefore, weth FLAG-TCAP, FLAG-Fbxl21, and HA-GSK-3b, and immunoprecipitation was
1 from 293T cells were used as kinase reaction substrates. One-way ANOVA
ctor) and FLAG-TCAP and FLAG-FBXL21 (*p < 0.05) and GSK-3b (***p < 0.001,
endent manner. Bottom panel: quantification of the effect of ectopic expression
.5 h; TCAP/GSK-3b, 5.2 h; TCAP/FBXL21, 2.3 h; TCAP/FBXL21/GSK-3b, 0.8 h.
ation. Right panel: quantification of the effect of CHIR-99021 on TCAP stability.
.9 h; TCAP/FBXL21, 3.1 h; TCAP/FBXL21/CHIR, 12.3 h.
anel: quantification of the effect of GSK-3b knockdown on TCAP stability. Error
h; TCAP/FBXL21, 1.1 h; TCAP/FBXL21/GSK-3b shRNA, 12.9 h.
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Figure 5. Identification of Phosphodegron Sites for TCAP and FBXL21 E3 Ligase Activity Regulation Sites
(A) Phosphorylated peptides, including S157 and S161, of TCAP were identified with high confidence by MS.
(B) The TCAP S157AS161Amutant showed decelerated degradation compared withWT TCAP. Bottom panel: quantification of the effect of FBXL21 onWT TCAP
and TCAP S157AS161A stability. Error bars represent ± SEM (n = 3). Half-life: TCAP, 5.5 h; TCAP/FBXL21, 3.2 h; TCAP S157AS161A, 6.8 h; TCAP S157AS161A/
FBXL21, 6.2 h.
(C) 293T cells were co-transfected with constructs expressing WT and chimeric FBXL21 (Figure S6A).
(D) The FBXL21 T33A and FBXL21 T33AS37A mutants showed reduced E3 ligase activity for TCAP. Right panel: quantification of TCAP degradation. Error bars
represent ± SEM (n = 3). Half-life: TCAP, 6.6 h; TCAP/FBXL21, 3.1 h; TCAP/FBXL21T33A, 5.4 h; TCAP/FBXL21T33AS37A, 8.3 h; the half-life parameter, K, is
significantly different.
(E) GSK-3b in vitro kinase assay. TCAP and FBXL21 GSK-3b target site peptides were used as kinase reaction substrates. Error bars represent ± SEM (n = 3).
One-way ANOVA shows significant statistical difference of the percentage of phosphorylation betweenmock (no substrate control) and the TCAP S161p peptide
(**p < 0.01) and the FBXL21 S37p peptide (*p < 0.05).
See also Figures S3 and S4.
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OPEN ACCESSgenerated chimeric FBXLs (Figure S3A) to narrow down func-
tional domains with E3 ligase activity for TCAP. All chimeric
FBXLs were found to bind to TCAP (Figure S3B). Compared
with WT FBXL21, moderately reduced but dose-dependent
TCAP degradation activity was observed from a chimeric protein
containing the FBXL21 N terminus (Figure 5C). In comparison, a
chimeric protein containing the FBXL3 N terminus did not show
TCAP degradation activity, suggesting a regulatory domain in
the N terminus of FBXL21 and not in the LRR (leucine-rich
repeat). In this N-terminal region, we found T33 as a candidate8 Cell Reports 32, 108140, September 15, 2020GSK-3b target site based on its consensus sequence. We there-
fore performed site-directed mutagenesis of T33 and S37
(candidate target and priming sites for GSK-3b). The T33A single
and T33A/S37A double mutants showed significant deficits in
TCAP degradation assays (Figure 5D), although their binding to
TCAP was not compromised (Figure S3C). Furthermore, in vitro
kinase assays showed that GSK-3b efficiently transferred phos-
phate groups to TCAP S157 and FBXL21 T33 peptides (Fig-
ure 5E). These results show direct GSK-3b phosphorylation of
TCAP S157 and FBXL21 T33 sites.
Figure 6. TCAP-FBXL21 and FBXL21-CULLIN1 Complex Formation Is Regulated by GSK-3b
Green and blue colors denote Venus and DAPI signals.
(A) TCAP and FBXL21 form a complex in the cytoplasm, and shGSK-3b co-transfection inhibits complex formation. Right panel: the bar graph shows mean ±
SEM from BiFC signal quantification; n = 3. One-way ANOVA shows that the relative fluorescence intensity is significantly statistically different between mock
(scramble shRNA) and GSK-3b shRNA. (***p < 0.001).
(B) FBXL21-CULLIN1 complex formation was significantly inhibited by shGSK-3b co-transfection. Right panel: the bar graph shows mean ± SEM of BiFC signal
quantification; n = 3. One-way ANOVA shows a significant statistical difference between mock and GSK-3b shRNA (****p < 0.0001).
(C) FBXL21-SKP1 complex formation was not affected by shGSK-3b co-transfection. Right panel: the bar graph shows mean ± SEM; n = 3. One-way ANOVA
shows that the relative fluorescence intensity is statistically not different. Scale bar, 20 mm.
(D) FBXL21T33A showed reduced Cullin1 complex formation compared with FBXL21. Right panel: the bar graph shows mean ± SEM; n = 3. One-way ANOVA
shows a significant statistical difference between Fbxl21 WT and Fbxl21T33A (***p < 0.001) and Fbxl21T33A.GSK-3b shRNA (****p < 0.0001). Scale bar, 20 mm.
See also Figure S5.
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we employed differentiated C2C12 cells (Zhang et al., 2012).
First we determined whether FBXL21 and TCAP are endoge-
nously expressed in differentiated C2C12 cells. On differentia-
tion day 2 after serum starvation, TCAP (Langley et al., 2002;
Markert et al., 2008) and FBXL21 were found to be expressed
in C2C12 cells, and expression persisted until day 5 (Figure S4A).
Next we used the GSK-3 inhibitors CHIR-99021 and lithium to
examine effects of FBXL21 inhibition on TCAP circadian oscilla-
tion. Importantly, consistent with the skeletal muscle tissue re-
sults (Figure 1E), we observed antiphasic circadian oscillations
of TCAP and FBXL21, which was abolished by GSK-3b inhibitor
treatment (Figure S4B). These results provide functional evi-dence that GSK-3b strongly regulates the reciprocal circadian
oscillations of TCAP accumulation and FBXL21 activity.
GSK-3b Regulates FBXL21-TCAP and FBXL21-SCF
Complex Formation
We performed bimolecular fluorescence complementation
(BiFC) assay (Kerppola, 2006) to investigate the role of GSK-3b
in FBXL21-TCAP and FBXL21-SCF complex formation (Figures
6 and S5). Specifically, VenN-FBXL21 (Venus N terminus fused
with Fbxl21) and VenC-TCAP (Venus C terminus fused with
TCAP) interaction was measured at the Venus emission wave-
length (528 nm). The FBXL21-TCAP complex was observed in
the cytoplasm, and GSK-3b shRNA co-transfection significantlyCell Reports 32, 108140, September 15, 2020 9
Figure 7. Psttm Mice Exhibit Impaired Muscle Function
(A) Frequency distribution of myotube diameter in gastrocnemius muscle from WT and Psttm mice. A t test shows that the distribution is significantly different
between WT and Psttm mice at 20–30, 30–40, and 40-50 (*p < 0.05) and 70–80 mm (**p < 0.01). Right: representative H&E staining images from WT and Psttm
mice. Scale bar, 50 mm.
(B) H&E staining images from differentiated control C2C12 cells and CRISPR-Cas9 sgFbxl21 cells. Right panel: quantification of myotube width (***p < 0.001).
Scale bar, 100 mm.
(C) Grip strength test (n = 10 for WT, n = 11 for Psttm).
(D–F) Treadmill assays of WT and Psttmmice at ZT6 (left panels) and ZT18 (right panels). Data are presented as mean ± SEM (n = 4–5). *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001.
(D) First fatigue measurements.
(legend continued on next page)






OPEN ACCESSinhibited FBXL21-TCAP complex formation (Figure 6A). To
examine a causal role of GSK-3b in FBXL21 activity regulation,
we used a VenN-Fbxl21 and VenC-Cullin1 BiFC pair, as reported
previously (Yoo et al., 2013). FBXL21-CULLIN1 complex forma-
tion primarily occurred in the cytoplasm (Figure 6B). GSK-3b
knockdown markedly impaired FBXL21-CULLIN1 complex for-
mation, suggesting that GSK-3b mediated FBXL21 phosphory-
lation is key for FBXL21 activation and SCF complex formation.
GSK-3b knockdown did not affect FBXL21-SKP1 complex for-
mation (Figure 6C), suggesting that phosphorylation of FBXL21
is required for the active stage of SCF complex formation (F
box-CULLIN1 complex formation) but not the default state of F
box protein binding to SKP1 (Reitsma et al., 2017). Finally, the
FBXL21 mutant harboring the GSK-3b target site mutation
(VenN-FBXL21T33A) showed significantly reduced CULLlN1
complex formation (Figure 6D). GSK-3b shRNA treatment further
decreased BiFC signals, suggesting additional GSK-3b phos-
phorylation sites other than T33.Smaller Fiber Size and Reduced Muscle Function in
Psttm Mutant Mice
To investigate the role of FBXL21 in skeletal muscle in vivo, we
compared muscle fiber diameter between WT and Psttm mice,
and the histogram result demonstrated a significant shift to
smaller fiber sizes in Psttm compared with the WT (Figure 7A).
There were differences in fiber diameter between WT and Psttm
at two circadian time points (ZT6 and ZT18) but no time-of-day ef-
fects for either genotype (Figure S6A). Muscle fiber type distribu-
tion showed no significant changes between WT and Psttm mice
(Figure S6B). Next we used CRISPR-Cas9 to delete Fbxl21 from
C2C12cells to investigate FBXL21 function duringmyotube differ-
entiation (Figures 7B and S6C). Deletion of Fbxl21 significantly
reducedmyotubewidth, consistent with Figure 7A and supportive
of a role of FBXL21 in regulating myotube diameter. On the other
hand, in WT mice and control C2C12 cells, muscle fiber diameter
did not oscillate as a function of circadian time, at least under the
tested conditions (Figures S6D and S6E).
To examine skeletal muscle function, we first subjected WT
and Psttmmice to a grip test to investigate muscle strength (Fig-
ure 7C). Compared with WT littermates, Psttm mice showed
significantly reduced grip strength for forelimbs and hindlimbs
at two circadian time points (ZT6 and ZT18). Next we performed
treadmill assays at ZT6 (daytime) and ZT18 (nighttime) to
compare their first fatigue, final exhaustion, and running dis-
tance. As shown in Figures 7D–7F, we observed significant dif-
ferences between WT and Psttm mice in final exhaustion and
running distance, with a trend of difference for first fatigue. The
functional differences between the genotypes were generally
greater and statistically significant at ZT18, indicating a requisite(E) Final exhaustion measurements.
(F) Running distance.
(G) Frequency distribution of myotube diameter in gastrocnemiusmuscle from sali
that the distribution is significantly different between control and Dex-treated WT
80–90 (***p < 0.001).
(H) Left panels: representative M mode images of WT and Psttm heart echoca
differences between WT (n = 9) and Psttm (n = 8) mice for SV, CO, EF, and FS (*
See also Figures S6 and S7.role of FBXL21 in muscle function during the active phase. For
example, WT mice showed a clear circadian pattern of running
distance with a strong increase from ZT6 (inactive) to ZT18
(active) (Figures 7F and S6F). Such a circadian pattern was dis-
rupted in Psttm mice, resulting in markedly dampened exercise
endurance at ZT18. On the other hand, in rotarod tests at both
circadian times, we did not observe significant differences be-
tween WT and Psttm mice (Figure S6G).
Skeletal muscle atrophy is caused by an imbalance of protein
synthesis and degradation, and GSK-3b has been shown to func-
tion in glucocorticoid-induced muscle atrophy (Bodine and Fur-
low, 2015; Schakman et al., 2008; Schiaffino et al., 2013; Verhees
et al., 2011). We investigated whether FBXL21 may function in
dexamethasone (Dex)-induced muscle atrophy (Gilson et al.,
2007; Sun et al., 2014). In WT mice, Dex significantly reduced
gastrocnemius muscle fiber size. Interestingly however, Psttm
mice showed resistance to Dex-induced fiber size reduction (Fig-
ures 7G and S6H), suggesting a role of the E3 ligase FBXL21 in
glucocorticoid-induced muscle atrophy. These results highlight
a pivotal physiological function of FBXL21 in skeletal muscle.
Finally, we examined cardiac muscle function. H&E staining,
Masson’s trichrome staining, and measurement of left ventricle
wall thickness did not reveal significant differences in gross
morphology and cardiomyocyte diameter betweenWT and Psttm
mice (Figures S7A–S7C). Interestingly, echocardiography showed
significant impairments in stroke volume (SV), cardiac output (CO),
ejection function (EF), and fraction shortening (FS), indicating an
important role of FBXL21 in heart function (Figure 7H). Consistent
with the H&E staining results, the echocardiographic dimensions
were similar in WT and Psttm mice, suggesting that functional
impairment precedes structural alteration (Figure S7D). These re-
sults support a regulatory role of FBXL21 in cardiac muscle.DISCUSSION
Core clock protein turnover, particularly via ubiquitination-medi-
ated proteasomal degradation by E3 ligases, plays critical roles
in regulating circadian rhythm (Gallego and Virshup, 2007; He
et al., 2005; Hirano et al., 2016; Koh et al., 2006; Liu et al., 2017;
Stojkovic et al., 2014). Previously, we reported two homologous
E3 ligases, FBXL3 and FBXL21, and demonstrated their antago-
nistic mechanism to fine-tune CRY turnover equilibrium (Yoo
et al., 2013). Here we identified TCAP as a substrate for the cyto-
plasm-specific E3 ligase activity of FBXL21.We showed circadian
oscillation of FBXL21 interactionwith TCAP,which is antiphasic to
the circadian pattern of TCAP protein accumulation. GSK-3b reg-
ulates TCAP degradation by co-phosphorylation of TCAP and
FBXL21; the latter was found to be important for FBXL21-
CULLIN1 complex formation and activation. In vivo studies furtherne- or dexamethasone (Dex)-treatedWT andPsttmmice (n = 3–4). T test shows
mice at 40–50 and 70–80 (*p < 0.05); 20–30, 30–40, and 60–70 (*p < 0.01); and
rdiographs. Right graphs: cardiac parameter measurements show significant
p < 0.05, ***p < 0.001, ****p < 0.0001).
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several skeletal muscle functions, including exercise endurance,
grip strength, and atrophy. These experiments illustrate a GSK-
3b-FBXL21 functional axis in skeletal muscle. Of note, echocardi-
ography revealed a role of FBXL21 in heart output function, poten-
tially contributing to the observed effects in vivo.
Skeletal muscle is increasingly appreciated as a key organ un-
der circadian control. Various aspects of skeletal muscle
biology, including gene expression, differentiation, contraction,
and metabolism, have been shown to interact with circadian
rhythms (Harfmann et al., 2015; Lefta et al., 2011). The current
study unveils a molecular pathway at the interface of skeletal
muscle biology and circadian rhythms. TCAP is localized at the
Z line of the sarcomere and has been implicated in sarcomere
assembly. TCAP knockout mice have been found to develop
heart failure with biomechanical stress (Knöll et al., 2011), and
human mutations in TCAP are associated with a form of auto-
somal recessive limb-girdle muscular dystrophy (AR LGMD)
type 2G and dilated cardiomyopathy (Chamova et al., 2018;
Francis et al., 2014; Hershberger et al., 2008; Hirtle-Lewis
et al., 2013; Knöll et al., 2002; Markert et al., 2010; Moreira
et al., 2000). We show that the circadian E3 ligase FBXL21 gov-
erns rhythmic accumulation of TCAP. Disruption of FBXL21
function in skeletal muscle alters TCAP stability and adversely af-
fects muscle structure and function. Several other E3 ligases
have been found to interact with TCAP, including MuRF1/2 and
MDM2 (Tian et al., 2006; Witt et al., 2005, 2008). MuRF1/2 inter-
action with TCAP has been found by Y2H, but their direct contri-
bution to TCAP degradation was not validated (Witt et al., 2005).
MDM2-mediated TCAP degradation was not dependent on the
ring finger domain (Tian et al., 2006), suggesting that MDM2 is
not the direct E3 ligase transferring Ub to TCAP. Herewe demon-
strate that FBXL21 is a requisite E3 ligase for TCAP proteasomal
degradation and that the Psttm hypomorph mutation disrupts
circadian oscillation of TCAP in skeletal muscle. Future studies
will investigate the possibility that TCAP oscillation may promote
diurnal structural remodeling in the sarcomere and dissect local
and systemic (e.g., heart) mechanisms by which TCAP dysregu-
lation in Psttm mice contributes to the observed in vivo pheno-
types, including fiber size and muscle function. Because E3 li-
gases are known to target many proteins for degradation,
investigation of substrates other than TCAP will further define
the mechanistic basis of FBXL21 function in vivo.
Compared with target substrate identification, upstream regu-
latory mechanisms governing E3 ligases are often not as well un-
derstood. Consistent with the growing evidence highlighting
PTMs as key regulatory events for E3 ligases (Fuchs et al.,
2002; Gao et al., 2009; Jura et al., 2006; Lin et al., 2009; Wang
et al., 2018; Xu et al., 2010), we report that GSK-3b regulates
FBXL21-CULLIN1 complex formation as a critical step of E3
ligase activation. TCAP phosphorylation is known to regulate
myofibrillogenesis, and PKD has been found to interact with car-
diac TCAP and function in the maintenance of transverse tubule
organization and intracellular Ca2+ transients in myocytes (Can-
dasamy et al., 2014; Mayans et al., 1998). However, a PKD-se-
lective inhibitor did not affect TCAP phosphorylation (Candas-
amy et al., 2014), suggesting that additional kinases (e.g.,
GSK-3b) are involved in TCAP phosphorylation. Inhibition of12 Cell Reports 32, 108140, September 15, 2020the other kinases tested in our assays did not alter TCAP accu-
mulation. Whether these other kinases serve additional roles in
TCAP regulation remains to be investigated.
GSK-3 kinases have been shown to cooperate with the SCF
E3 ligase b-TRCP, targeting more than 20 substrates for degra-
dation by b-TRCP (Robertson et al., 2018). GSK-3s regulate
circadian rhythms by various mechanisms. In Drosophila, the
GSK-3 homolog Shaggy (sgg) phosphorylates TIMELESS, which
induces nuclear translocation of the PER/TIM dimer (Martinek
et al., 2001). In mammals, GSK-3b has been shown to phosphor-
ylate five core clock proteins, including PER2, CRY2, CLOCK,
BMAL1 and REV-ERBa (Kaladchibachi et al., 2007; Kurabayashi
et al., 2010; Sahar et al., 2010; Spengler et al., 2009; Yin et al.,
2006). Double knockin mice expressing constitutively active
forms of GSK-3a and GSK-3b showed altered circadian rhythms
(Paul et al., 2012). Furthermore, inhibition of GSK-3b can lead to
period lengthening by lithium (Li et al., 2012) or shortening (Hirota
et al., 2008) by other small-molecule GSK-3b inhibitors.We show
here that FBXL21 ubiquitinates TCAP via a GSK-3b target phos-
phodegron; the FBXL21 E3 ligase activity is itself regulated by
GSK-3b phosphorylation, suggesting a co-phosphorylation
mechanism. Therefore, although both GSK-3b and FBXL21
regulate the core oscillator and modify rhythmic behavior, our
study links them in a functional pathway, revealing circadian
regulation of protein turnover by the GSK-3b-FBXL21 axis.
GSK-3 signaling orchestrates broad physiological functions
(Beurel et al., 2015). For example, GSK-3b is a negative modu-
lator underlying the anabolic insulin growth factor 1 (IGF-1)/
AKT pathway, known to stimulate muscle protein synthesis
and inhibit muscle protein degradation (Glass, 2005). A kinase-
inactive form of GSK-3b and pharmacological inhibition of
GSK-3b induce hypertrophy (Rommel et al., 2001; Vyas et al.,
2002) and have been applied as interventions for skeletal muscle
atrophy (Verhees et al., 2011). GSK-3b in particular promotes
muscle protein degradation in response to glucocorticoids
(Schiaffino et al., 2013; Verhees et al., 2011). Although previous
studies highlighted a key role of proteasomal degradation in
GSK-3b regulated muscle protein turnover, direct regulation of
E3 ligase activity by GSK-3 and the molecular mechanism of
myofibrillar protein degradation have not been reported. We re-
vealed a direct link of GSK-3b and FBXL21-mediated TCAP
degradation and demonstrated defective glucocorticoid-
induced muscle atrophy in Psttm mice. These results suggest
a regulatory function of GSK-3b-FBXL21 that may be targeted
to alleviate muscle dystrophy, commonly observed in disease
and aging conditions.
In conclusion, we identified a cytoplasmic substrate, TCAP, for
the circadian E3 ligase FBXL21, and FBXL21 deficiency led to
impaired skeletal muscle function. Mechanistically, we uncov-
ered GSK-3b as a key upstream regulator, phosphorylating
TCAP and FBXL21 and promoting SCF complex formation for
TCAP degradation. These studies highlight a GSK-3b-FBXL21
axis in circadian regulation of muscle physiology.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
Article
ll




B Data and Code Availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Animal studies
B Cell culture, differentiation and CRISPR
d METHOD DETAILS
B Yeast 2-hybrid (Y2H) screen
B Cell culture transfection
B Immunoblotting, immunoprecipitation and immunocy-
tochemistry
B Liquid Chromatography-Mass Spectrometry Analysis
B In vitro kinase assay
B TCAP and Fbxl21 mutants
B Bimolecular Fluorescence Complementation (BiFC)
Assay
B Real-time qPCR
B Muscle fiber and myotube measurements
B Treadmill exercise, grip strength, and Rotarod tests
B Echocardiography and heart histology
d QUANTIFICATION AND STATISTICAL ANALYSISSUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
celrep.2020.108140.ACKNOWLEDGMENTS
We thank J. Choi, Y. Kim, S. Yan, T. Hu, and E. Deng for technical assistance
and H. Shelat for helpful discussions. This work is in part supported by The
Welch Foundation (AU-1971-20180324) and NIH/NIGMS (R01GM114424) (to
S.-H.Y.), The Welch Foundation (AU-1731-20190330) and NIH/NIA
(R01AG045828, R56AG063746, and R01AG065984) (to Z.C.), The NMSS
Foundation (RG 1508-08406) and the Hilton Foundation (17328) (to H.K.L.),
and NIH (R01AR066082 to K.A.E.). The BCM Mass Spectrometry Proteomics
Core is supported by a Dan L. Duncan Comprehensive Cancer Center NIH
award (P30 CA125123) and a CPRIT Core Facility Award (RP170005) (to
S.Y.J.).AUTHOR CONTRIBUTIONS
S.-H.Y. conceived and designed the project. S.-H.Y., Z.C., Y.-J.G., H.K.L., and
S.Y.J. supervised the research. M.W., J.Y., E.K., S.G., K.R.P., J.M.C., J.C.,
G.F.G., P.A., R.P., H.K.L., and S.-H.Y. conducted the research. All authors
contributed to the experimental design and data analysis. S.-H.Y. prepared
themanuscript draft. All authors provided additional information and/or critical
comments.DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: September 27, 2019
Revised: January 4, 2020
Accepted: August 21, 2020
Published: September 15, 2020REFERENCES
Adler, G., Konrad, Z., Zamir, L., Mishra, A.K., Raveh, D., and Bar-Zvi, D. (2017).
The Arabidopsis paralogs, PUB46 and PUB48, encoding U-box E3 ubiquitin
ligases, are essential for plant response to drought stress. BMC Plant Biol.
17, 8.
Beurel, E., Grieco, S.F., and Jope, R.S. (2015). Glycogen synthase kinase-3
(GSK3): regulation, actions, and diseases. Pharmacol. Ther. 148, 114–131.
Blom, N., Sicheritz-Pontén, T., Gupta, R., Gammeltoft, S., and Brunak, S.
(2004). Prediction of post-translational glycosylation and phosphorylation of
proteins from the amino acid sequence. Proteomics 4, 1633–1649.
Bodine, S.C., and Furlow, J.D. (2015). Glucocorticoids and Skeletal Muscle.
Adv. Exp. Med. Biol. 872, 145–176.
Busino, L., Bassermann, F., Maiolica, A., Lee, C., Nolan, P.M., Godinho, S.I.H.,
Draetta, G.F., and Pagano, M. (2007). SCFFbxl3 controls the oscillation of the
circadian clock by directing the degradation of cryptochrome proteins. Sci-
ence 316, 900–904.
Candasamy, A.J., Haworth, R.S., Cuello, F., Ibrahim, M., Aravamudhan, S.,
Kr€uger, M., Holt, M.R., Terracciano, C.M., Mayr, M., Gautel, M., and Avkiran,
M. (2014). Phosphoregulation of the titin-cap protein telethonin in cardiac my-
ocytes. J. Biol. Chem. 289, 1282–1293.
Cederroth, C.R., Albrecht, U., Bass, J., Brown, S.A., Dyhrfjeld-Johnsen, J.,
Gachon, F., Green, C.B., Hastings, M.H., Helfrich-Förster, C., Hogenesch,
J.B., et al. (2019). Medicine in the Fourth Dimension. Cell Metab. 30, 238–250.
Chamova, T., Bichev, S., Todorov, T., Gospodinova, M., Taneva, A., Kastreva,
K., Zlatareva, D., Krupev, M., Hadjiivanov, R., Guergueltcheva, V., et al. (2018).
Limb girdle muscular dystrophy 2G in a religious minority of Bulgarian Muslims
homozygous for the c.75G>A, p.Trp25X mutation. Neuromuscul. Disord. 28,
625–632.
Dardente, H.,Mendoza, J., Fustin, J.M., Challet, E., andHazlerigg, D.G. (2008).
Implication of the F-Box Protein FBXL21 in circadian pacemaker function in
mammals. PLoS ONE 3, e3530.
Eide, E.J., Woolf, M.F., Kang, H., Woolf, P., Hurst, W., Camacho, F., Vielhaber,
E.L., Giovanni, A., and Virshup, D.M. (2005). Control of mammalian circadian
rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation.
Mol. Cell. Biol. 25, 2795–2807.
Filipcı́k, P., Curry, J.R., and Mace, P.D. (2017). When Worlds Collide-Mecha-
nisms at the Interface between Phosphorylation and Ubiquitination. J. Mol.
Biol. 429, 1097–1113.
Francis, A., Sunitha, B., Vinodh, K., Polavarapu, K., Katkam, S.K., Modi, S.,
Bharath, M.M., Gayathri, N., Nalini, A., and Thangaraj, K. (2014). Novel
TCAP mutation c.32C>A causing limb girdle muscular dystrophy 2G. PLoS
ONE 9, e102763.
Fuchs, S.Y., Lee, C.G., Pan, Z.Q., and Ronai, Z. (2002). Retraction. Cell 110,
531.
Fuchs, S.Y., Spiegelman, V.S., and Kumar, K.G. (2004). The many faces of
beta-TrCP E3 ubiquitin ligases: reflections in themagic mirror of cancer. Onco-
gene 23, 2028–2036.
Gallego, M., and Virshup, D.M. (2007). Post-translational modifications regu-
late the ticking of the circadian clock. Nat. Rev. Mol. Cell Biol. 8, 139–148.
Gao, D., Inuzuka, H., Tseng, A., Chin, R.Y., Toker, A., and Wei, W. (2009).
Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and im-
pairs APCCdh1-mediated Skp2 destruction. Nat. Cell Biol. 11, 397–408.
Gilson, H., Schakman, O., Combaret, L., Lause, P., Grobet, L., Attaix, D., Ke-
telslegers, J.M., and Thissen, J.P. (2007). Myostatin gene deletion prevents
glucocorticoid-induced muscle atrophy. Endocrinology 148, 452–460.
Glass, D.J. (2005). Skeletal muscle hypertrophy and atrophy signaling path-
ways. Int. J. Biochem. Cell Biol. 37, 1974–1984.
Godinho, S.I., Maywood, E.S., Shaw, L., Tucci, V., Barnard, A.R., Busino, L.,
Pagano, M., Kendall, R., Quwailid, M.M., Romero, M.R., et al. (2007). The af-
ter-hours mutant reveals a role for Fbxl3 in determining mammalian circadian
period. Science 316, 897–900.Cell Reports 32, 108140, September 15, 2020 13
Article
ll
OPEN ACCESSGreen, C.B. (2018). Circadian Posttranscriptional Regulatory Mechanisms in
Mammals. Cold Spring Harb. Perspect. Biol. 10, a030692.
Gregorio, C.C., Trombitás, K., Centner, T., Kolmerer, B., Stier, G., Kunke, K.,
Suzuki, K., Obermayr, F., Herrmann, B., Granzier, H., et al. (1998). The NH2 ter-
minus of titin spans the Z-disc: its interaction with a novel 19-kD ligand (T-cap)
is required for sarcomeric integrity. J. Cell Biol. 143, 1013–1027.
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Rabbit polyclonal anti-CUL1 Cell Signaling Technology Cat# 4995; RRID:AB_2261133
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Rabbit polyclonal anti-Lamin B1 abcam Cat# ab16048; RRID:AB_443298
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Mouse monoclonal anti-GAPDH
Monoclonal Antibody (6C5)
Thermofisher Cat# AM4300; RRID:AB_2536381
Mouse monoclonal anti-Telethonin (clone
53)
BD Cat# 612328; RRID:AB_399643
Rabbit polyclonal anti-GSK-3b (D5C5Z) Cell Signaling Technology Cat# 12456; RRID:AB_2636978
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Mouse monoclonal anti-myosin heavy
chain Type I
DSHB BA-D5; RRID:AB_2235587
Mouse monoclonal anti-myosin heavy
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Bacterial and Virus Strains
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Bacteria strain Stbl3 ThermoFisher Cat# C737303
Biological Samples
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JAX Cat# 000664
WT littermates of Psttm homizygouse mice,
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In house N/A
Psttm homozygous mice, skeletal muscle
tissue from mouse
In house N/A
Chemicals, Peptides, and Recombinant Proteins
CHIR-99021 Selleckchem Cat# S2924
Ro3306 Selleckchem Cat# S7747
NU7441 Selleckchem Cat# S2638
Sotrastaurin Selleckchem Cat# S2791




FBXL21S37p (RGLCSSLRQTHALSpVLLD) GenScript N/A
Critical Commercial Assays
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Z-lyte Kinase Assay Invitrogen Cat# PV3324
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Human: 293T cells ATCC CRL-3216; RRID:CVCL_0063
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Experimental Models: Organisms/Strains
Mouse: C57BL/6J The Jackson Laboratory JAX 000664; RRID:IMSR_JAX:000664
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Recombinant DNA
pCMV10-3XFlag-TCAP This paper N/A
VenusN-TCAP This paper N/A
VenusN-Fbxl21 This paper N/A
LentiCRISPR v2 Addgene Cat#52961; RRID:Addgene_80089
pLKO.1-GSK-3b-1 Addgene Cat# 32496
pLKO.1-GSK-3b-2 Addgene Cat# 32497
Software and Algorithms
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Materials Availability
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Agreement (MTA) may apply.
Data and Code Availability
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal studies
C57BL/6J (Stock # 000664) mice were purchased from the Jackson Laboratory (Bar Harbor, ME); Psttm and littermateWTmice were
maintained in house. All mice were housed under LD12:12 unless otherwise noted. All animal studies, using male mice at the age of
10-17 weeks, were approved by UTHealth Center for Laboratory Animal Medicine and Care (CLAMC).Cell Reports 32, 108140, September 15, 2020 e2
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293T (ATCC: CRL-3216) cells and C2C12 (ATCC: CRL-1772) were cultured in DMEM supplemented with 10% fetal bovine serum
(GenDEPOT). For C2C12 differentiation, cells were maintained in DMEMwith 10% FBS and penicillin/streptomycin until 90% conflu-
ence. Cells were incubated in differentiation media (DMEM containing 2% horse serum and penicillin/streptomycin). Differentiation
media were changed daily until cells were fully differentiated (around day 5). Cells were synchronized by Dexamethasone (Dex,
200 nM) for 1 hr, and collected every 4 hr. To generate Fbxl21 CRISPR cell lines, the sense and antisense guide RNAs (Table S1)
were designed (https://crispr.dbcls.jp) and cloned into the BsmB1 site of the LentiCRISPR v2. C2C12 cells were transfected and
selected for single colonies survived from puromycin selection.
METHOD DETAILS
Yeast 2-hybrid (Y2H) screen
Y2H was performed with the AH109 strain (Panbionet). Bait plasmids express FBXL3 and FBXL21 fused with the GAL4 DNA binding
domain. Briefly, Fbxl3 (82-428 aa) and Fbxl21 (86-434 aa) were cloned into EcoRl/BamHI sites of the pGBKT7 vector. Cry2 was
cloned into XmaI/SalI digested pGADT7 plasmids to serve as a positive control. The interaction between bait and prey proteins re-
constitutes the function of GAL4 and activates reporter gene expression. Positive control yeasts were transformedwith the pGBKT7-
p53 bait plasmid and the pGADT7-SV40 Tag prey plasmid. pGBKT7-p53 encodes the Gal4 DNA-BD fused with murine p53;
pGADT7-T encodes the Gal4 AD fused with SV40 large T-antigen. Cells transformed with the parental bait vector (pGBKT7) and
the prey vector (pACT2) were used as negative controls. Transformants were incubated in SD-LW, SD-LWA and SD-LWHmedia con-
taining 5 mM of 3-AT(3-amino-1,2,3-triazole), a competitive inhibitor of the yeast HIS3 protein (His3p) at 30C. SD-LW, SD-LWA and
SD-LWH indicate synthetic complete media devoid of leucine/tryptophan, leucine/tryptophan/adenine and leucine/tryptophan/his-
tidine respectively. Among > 30 positive interaction hits, we validated interaction of several top candidates by co-IP with FBXLs, with
validation of other candidates currently on-going. For this study, we chose to focus on TCAP because it was recently found to be
encoded by a clock-controlled gene (Podobed et al., 2014).
Cell culture transfection
293T (ATCC CRL-3216) cells and C2C12 (ATCC CRL-1772) were cultured in DMEM supplemented with 10% fetal bovine serum
(GenDEPOT). For immunoprecipitations, 23 106 cells were plated into 60 mm dishes 1 day before transfection, and iMFectin (Gen-
DEPOT) was used to transfect DNA according to the manufacturer’s protocol. M2 agarose bead (Sigma) was used to pull down flag
tagged proteins. TCAP degradation assays were performed by transfecting pCMV10-3XFlag-TCAP with or without Fbxl3 and Fbxl21
expression constructs into 2 3 105 293T cells in a 12-well plate. Thirty-six hours after transfection 100 mg/ml cycloheximide (CHX)
was added and cells collected at the indicated times. The incubation time length was chosen to avoid significant cytotoxicity while
still sufficient to distinguish effects. Half-life was determined by using nonlinear, one-phase decay analysis (GraphPad Prism). siRNA
for hFbxl21 was purchased from Dharmacon and transfection was performed by using Lipofectamine 2000 (Invitrogen). CHIR99021,
Ro3306, NU7441, Sotrastaurin, and IC261 were purchased from Selleckchem.
Immunoblotting, immunoprecipitation and immunocytochemistry
Immunoblotting, immunoprecipitation and immunocytochemistry were performed as described previously (Siepka et al., 2007; Yoo
et al., 2013). For ectopic expression of Flag-TCAP, Flag-FBXL3 and Flag-FBXL21 we used Flag-HRP antibody (Sigma). For endog-
enous TCAP expression detection from skeletal muscle and C2C12 samples, we used anti-TCAP antibody (BD). Antibodies against
FBXL21 and BMAL1 were generated using guinea pig, rabbit or chicken (Cocalico Biologicals) as described previously (Nohara et al.,
2019; Yoo et al., 2013) and serum was affinity purified using the same protein or peptide used to raise the antibody. Commercial
vendors of antibodies used include BD (TCAP), Invitrogen (anti-Skp1, anti-Cullin1), Santa Cruz (b- actin, a-tubulin), Abcam (anti-Lam-
inB1), Sigma (anti-Flag-HRP, anti-HA-HRP, M2 bead), GAPDH (Ambion). Nuclear fractionation and ubiquitination assays were per-
formed as described before (Yoo et al., 2013). Muscle fiber typing was performed as described previously (Schroder et al., 2015). We
used BA-D5 (Type I), SC-71 (Type IIa) and BF-F3 (Type IIb) from DSHB (Developmental Studies Hybridoma Bank).
Liquid Chromatography-Mass Spectrometry Analysis
Affinity-purified proteins were separated by SDS-PAGE. Protein bands were digested in gel with various enzymes including Trypsin,
Chymotrypsin or GluC to increase identification coverage. Digested peptides were extracted from gel and separated by Ultimate
3000 nano-LC system (Thermo Scientific). Separated peptides were directly electro-sprayed and injected into Orbitrap Fusion Tribrid
system (Thermo Fisher Scientific) in data-dependent mode. Top 50 precursors were fragmented and spectra acquired in CID mode.
Obtained spectra were searched and validated by using Proteome Discoverer 1.4 interfaced with Mascot algorism (Mascot 2.4, Ma-
trix Science).
In vitro kinase assay
Flag-TCAP and Flag-FBXL21 were ectopically expressed and affinity purified from 293T cells, with cells transfected with the Flag-
pCMV10 empty vector as a mock control. These proteins and TCAP S161p (GPLRRTLSRSMSpQEAQRG), FBXL21S37pe3 Cell Reports 32, 108140, September 15, 2020
Article
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Enzyme System with ADP-Glo Kinase Assay (Promega) or Z’-Lyte Kinase Assay (Invitrogen).
TCAP and Fbxl21 mutants
Site-directed mutagenesis of Flag-TCAP, Flag-Fbxl21, VenusN-Fbxl21, and VenusN-TCAP to construct lysine or serine revertant
clones and FBXLs chimeric construct were performed by using primers listed in Table S1.
Bimolecular Fluorescence Complementation (BiFC) Assay
BiFC experiments were performed as described previously (Yoo et al., 2013). PCR amplified TCAP cDNA was cloned into KpnI and
BamHI sites of VenC. Briefly, VenN-TCAP or VenN-Fbxls and VenC-Skp1 or VenC-Cullin were transfect to 3x105 293T cells using
iMFectin (GenDEPOT). GSK-3b shRNAs (pLKO.1-GSK-3b-1, Addgene #32496; pLKO.1-GSK-3b-2, Addgene #32497) are co-trans-
fected in indicated experiments. Media were changed after overnight incubation at 37C, 5% CO2. Plates were washed with PBS
once 2 days after transfection and fixed with 4% paraformaldehyde in PBS for 15 min. Samples were stained with DAPI (1 ug/ml),
washed twice, immersed with PBS and sealed with top-seal A membrane (Perkin-Elmer). Fluorescence images were acquired
with Zeiss Imager.M2m equipped with ApoTome.2, Axiocam 506 mono and AxioCamMRc. Images were captured using Zen2 Soft-
ware. Seven locations in each slide were selected. Imageswere taken in the channel sequence of FITC (Ex 493, Em 528) andDAPI (Ex
390, Em 435) filter sets. For quantification of BiFC results, original image files were imported to NIH ImageJ (Schneider et al., 2012) for
quantification. Briefly, cytoplasm were recognized based on FITC fluorescence (regions with no fluorescence considered as back-
ground) and corrected total cell fluorescence (CTCF) was calculated by integrated density. About 100 cells were identified and
measured in each image, and the average values of cells in one image were obtained for further normalization and statistical analysis.
Seven images from each slide were averaged and the experiments were repeated three times.
Real-time qPCR
Total RNA was extracted from cells or frozen tissue by using TRizol (Invitrogen). Two microgram of total RNA were used for cDNA
synthesis (GenDEPOT). Gene expression was analyzed by using Stratagene Mx3000p (Agilent).
Muscle fiber and myotube measurements
WT C57BL/6J (n = 3) and homozygous Psttm (n = 3) littermate mice at 12-13 weeks of age were sacrificed. Gastrocnemius muscles
were isolated in 10% Formaldehyde and embedded in paraffin. Cross sections (10 mM) of the gastrocnemius muscle were stained
with Hematoxylin and Eosin and images were acquired at 100x magnification using a high-resolution camera Olympus DP71
(Olympus) attached to a BX60 microscope (Olympus). Five hundred myotube fibers were analyzed from each animal and average
muscle fiber diameters were quantified using ImageJ (NIH). For Dex-induced muscle atrophy experiment (n = 3), WT and Psttm litter-
mate mice were injected s.c. with either saline (0.9% NaCl) or Dex (5 mg/kg) for 7 days, and muscle fiber size measurements were
conducted as above. C2C12 control and sgRNA (Fbxl21 CRISPR) cell lines were cultured and differentiated as indicated above. Fully
differentiated cells were fixed with 4% Paraformaldehyde, stained with Hematoxylin and Eosin and images were acquired and
analyzed as above.
Treadmill exercise, grip strength, and Rotarod tests
Treadmill exercise test was performed largely as previously described (Nohara et al., 2019) with minor modifications. WT (n = 5) and
Psttm (n = 4) mice at16weeks of age were acclimated to the Exer-3R treadmill (Columbus Equipment) for 3 times over 4 days. After
a week of recovery, the mice were tested in the treadmill with an initial speed of 7 m/ min. The speed was gradually increased at the
rate of 2 m/min every 5 minutes. The assay was done twice at both ZT6 and ZT18 with two weeks of recovery between the different
time points. Three measurements, including first fatigue (the first 15 s that mice stay at the electric stimulation area), final exhaustion
(the total running time of the mice) and running distance, were taken for each assay.
For grip test, WT (n = 11) and Psttm (n = 12) adult mice were tested by using BIO-GS3Grip Test instrument (Bioseb). Each test were
performed twice at ZT6 and ZT18. At each time point, three measurements were taken for both forelimb and hindlimb.
For Rotarod test, WT (n = 11) and Psttm (n = 12) adult mice were tested by using Touchscreen Rotarod (Panlab/ Harvard Appa-
ratus). The mice were first acclimated to the stationary rod for 1 min at a base speed of 4 rpm for 5 mins. After the acclimation,
the mice were tested with the increasing speed of 4 - 40 rpm for 5 mins. The latency to fall for each mouse was measured for two
days at both ZT6 and ZT18.
Echocardiography and heart histology
Heart function in WT and Psttm littermate mice (age: 10 weeks) was evaluated with echocardiomyography. M-Mode echocardio-
graphic images were recorded using Vevo 770 echocardiography equipped with a 40-MHz RMV704 ultrasonic probe (Visual Sonics,
Toronto, Canada). M-mode images were then captured in the long axes. Each image loop provided 15 to 20 heart cycles; M-mode
data were averaged from at least 3 cycles per loop. The cardiac parameter including left ventricle ejection function (EF), fractionCell Reports 32, 108140, September 15, 2020 e4
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OPEN ACCESSshortening (FS), cardiac output (CO) and stroke volume (SV), heart dimensions such as intraventricular septum (IVS), left ventricular
internal dimension (LVID) and left ventricle posterior wall (LVPW) were measured according to the American Society of Echocardiog-
raphy’s leading edge technique.
For heart histology,WTC57BL/6J and Psttm (n = 5) littermatemice, age 16-17weeks of age, were sacrificed. Hearts were isolated,
fixed with 10% Formaldehyde and embedded in paraffin. Heart coronal sections were stained with Hematoxylin and Eosin and Mas-
son Trichome. Images were captured with Aperio LV1 (Leica Biosystems) and quantified using LV1 console (Leica Biosystems).
QUANTIFICATION AND STATISTICAL ANALYSIS
Results are presented asmean ± SEM unless otherwise stated. Data were analyzed using Student’s t test, one-way ANOVA followed
by post hoc analysis using Dunnett’smultiple comparison test or two-way ANOVA followed by post hoc analysis using Bonferroni test
as offered by GraphPad Prism. A value of p < 0.05 was considered statistically significant.e5 Cell Reports 32, 108140, September 15, 2020
